Article · 27 Dec 2024
Conference abstractPublished 10 Aug 2017
Some considerations about biosimilar safety
Al-Qasim Green University, Iraq
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Biosimilar safety is an important step to be approved. Biosimilar safety is related with the adverse drug reactions as a result of their pharmacological actions and immunogenicities. The purpose of this study is to describe some considerations about biosimilar safety such as naming, immunogenicity, manufacturing, pharmacovigilance, interchangeability, labeling, preclinical studies, clinical studies and post-approval studies. Methodology & Theoretical Orientation: Naming of biosimilar is an important step to differentiate biosimilar from the reference product as a part of safety. Biosimlars are proteins having capacity of inducing immune response that may be humoral or cellular. Small manufacturing alterations in the source materials or production process of any biologic product may lead to changes in molecular structure and potentially its biologic effects. Pharmacovigilance planning include efforts beyond post marketing spontaneous reporting and designed for enhancing and expedite the biosimilar manufacturerâÂ?Â?s acquisition of safety information. Biosimilars, to be approved interchangeable, it must meet a higher standard by producing the same clinical result as the reference product in any given patient. The labeling is important to decide whether a specific adverse event/safety issue for biosimilar is already identified as a risk or could be a new potential safety issue. Preclinical studies used animal models to preliminarily assess toxicity, including immunogenicity. Clinical studies include an assessment of immunogenicity and PK or pharmacodynamics (PD). Finally, the need for post-approval studies to establish efficacy in indications was not studied during the approval process and long-term safety studies. Findings: Biosimilar is a new pharmaceutical product and its safety approval is very important. Conclusion & Significance: Naming of biosimilar is an important step for safety and immunogenicity study is important for safety assessment. Biosimilars, to be approved interchangeable, must meet a higher standard and preclinical studies, clinical studies, postapproval studies, must be achieved. Recommendations: Reaching to unified name, standard definition for biosimilar and close guideline and demonstration of other aspects about biosimilar safety is recommended.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Apr 2019
Biosimilars: Stability and quality considerations
Conference abstract · 10 Aug 2017
Considerations in biosimilars commercialization
Conference abstract · 15 May 2017
CMC considerations for biosimilar drug development
Conference abstract · 27 Jun 2016
Analytical Assessment of Biosimilarity – Considerations in Study Design
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Samer M Al-Hulu”

